Recently, increasing evidence has shown the association between liver abnormal inflammation and cognition impairment, yet their age-related pathogenesis remains obscure. Here, our study provides a potential&#
xa0;mechanistic link between liver macrophage excessive activation and neuroinflammation in aging progression. In aged and LPS-injected C57BL/6J mice, systemic administration of &#
x3b2;-chitosan ameliorates hepatic macrophage-driven inflammation and reduces peripheral accumulations of TNF-&#
x3b1; and IL-1&#
x3b2;. Downregulation of circulatory pro-inflammatory cytokines then decreases vascular VCAM1 expression and neuroinflammation in the hippocampus, leading to cognitive improvement in aged/LPS-stimulated mice. Interestingly, &#
x3b2;-chitosan treatment also exhibits the beneficial effects on the behavioral recovery of aged/LPS-stimulated zebrafish and <i>Caenorhabditis elegans</i>. In our cell culture and molecular docking experiments, we found that &#
x3b2;-chitosan prefers shielding the MD-2 pocket, thus blocking the activation of TLR4-MD-2 complex to suppress NF-&#
x3ba;B signaling pathway activation. Together, our findings highlight the extensive therapeutic potential of &#
x3b2;-chitosan in reversing aged-related/LPS-induced cognitive impairment via the liver-brain axis.